SMS Lifesciences India Limited, originally incorporated as Potluri Real Estate Private Limited in 2006, operates in the pharmaceutical sector, focusing on the manufacturing and export of Active Pharma Ingredients (APIs) and their intermediates. The company has evolved from a single-product facility to a multi-location entity with facilities in Kazipally and Jeedimetla, Hyderabad, boasting an installed capacity of 65 KL. SMS Lifesciences became a wholly-owned subsidiary of SMS Pharmaceuticals Limited in 2016 and transitioned to a public limited company shortly after.
The company gained export house status in 1997-98 and has expanded its operations to include three multi-product facilities and a research center. Following a scheme of demerger from SMS Pharmaceuticals Limited in 2017, SMS Lifesciences acquired several semi-regulated facilities and premises, enhancing its manufacturing capabilities. It briefly acquired Mahi Drugs Private Limited as a wholly-owned subsidiary in 2018, later reducing its stake by 10% in 2022.
